The incremental cost per life year saved of atorvastatin versus fluvastatin for the primary prevention of CHD in men with no other risk factors ranged from $8,889 to $27,819.
The incremental cost per life year saved of atorvastatin versus fluvastatin for the primary prevention of CHD in men with three other risk factors ranged from $865 to $6,998.
The incremental cost per life year saved of atorvastatin versus fluvastatin for the secondary prevention of CHD in men with no other risk factors ranged from $6,169 to $10,639.
The incremental cost per life year saved of atorvastatin versus fluvastatin for the secondary prevention of CHD in men with other risk factors ranged from $4,665 to $7,983.
The incremental cost per life year saved of atorvastatin versus fluvastatin for the primary prevention of CHD in women with no other risk factors ranged from $106,985 to $185,608.
The incremental cost per life year saved of atorvastatin versus fluvastatin for the primary prevention of CHD in women with three other risk factors ranged from $13,580 to $30,715.
The incremental cost per life year saved of atorvastatin versus fluvastatin for the secondary prevention of CHD in women with no other risk factors ranged from $13,491 to $22,512.
The incremental cost per life year saved of atorvastatin versus fluvastatin for the secondary prevention of CHD in women with one other risk factors ranged from $6,122 to $10,954.
Atorvastatin therapy cost less and was more effective than fluvastatin, lovastatin, simvastatin, and pravastatin when model parameters were varied. When atorvastatin's effect on LDL levels was varied, its cost-effectiveness versus no therapy varied from $9,000 to $8,000 for the highest risk profile and from $300,000 to $267,000 for the lowest risk profile.